99 related articles for article (PubMed ID: 10481924)
1. Sialic acid content of LDL and lipoprotein metabolism in combined hyperlipidemia and primary moderate hypercholesterolemia.
Lindbohm N; Gylling H; Miettinen TE; Miettinen TA
Clin Chim Acta; 1999 Jul; 285(1-2):69-84. PubMed ID: 10481924
[TBL] [Abstract][Full Text] [Related]
2. Statin treatment increases the sialic acid content of LDL in hypercholesterolemic patients.
Lindbohm N; Gylling H; Miettinen TE; Miettinen TA
Atherosclerosis; 2000 Aug; 151(2):545-50. PubMed ID: 10924733
[TBL] [Abstract][Full Text] [Related]
3. Sialic acid content of low density lipoprotein and its relation to lipid concentrations and metabolism of low density lipoprotein and cholesterol.
Lindbohm N; Gylling H; Miettinen TA
J Lipid Res; 2000 Jul; 41(7):1110-7. PubMed ID: 10884293
[TBL] [Abstract][Full Text] [Related]
4. Sialic acid and oxidizability of low density lipoprotein subfractions of hyperlipidemic patients.
Barbosa DS; Maranhão RC; Araújo FB; Chang YH; Hirata MH; Abdalla DS
Clin Biochem; 1995 Aug; 28(4):435-41. PubMed ID: 8521599
[TBL] [Abstract][Full Text] [Related]
5. Sialic acids and the metabolism of low density lipoprotein.
Melajärvi N; Gylling H; Miettinen TA
J Lipid Res; 1996 Aug; 37(8):1625-31. PubMed ID: 8864946
[TBL] [Abstract][Full Text] [Related]
6. Sialic acid content of low-density lipoprotein in women with coronary artery disease.
Lindbohm N; Gylling H; Rajaratnam RA; Miettinen TA
J Lab Clin Med; 2000 Aug; 136(2):110-5. PubMed ID: 10945239
[TBL] [Abstract][Full Text] [Related]
7. Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans.
Anber V; Millar JS; McConnell M; Shepherd J; Packard CJ
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2507-14. PubMed ID: 9409221
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of low-density lipoprotein subfractions from patients with coronary artery disease.
Jaakkola O; Solakivi T; Tertov VV; Orekhov AN; Miettinen TA; Nikkari T
Coron Artery Dis; 1993 Apr; 4(4):379-85. PubMed ID: 8261211
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of low density lipoproteins in nephrotic dyslipidemia: comparison of hypercholesterolemia alone and combined hyperlipidemia.
Vega GL; Toto RD; Grundy SM
Kidney Int; 1995 Feb; 47(2):579-86. PubMed ID: 7723244
[TBL] [Abstract][Full Text] [Related]
10. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
[TBL] [Abstract][Full Text] [Related]
11. Sialic acid-containing components of lipoproteins influence lipoprotein-proteoglycan interactions.
Millar JS; Anber V; Shepherd J; Packard CJ
Atherosclerosis; 1999 Aug; 145(2):253-60. PubMed ID: 10488950
[TBL] [Abstract][Full Text] [Related]
12. Hyperlipidemia in coronary heart disease. 3. Evaluation of lipoprotein phenotypes of 156 genetically defined survivors of myocardial infarction.
Hazzard WR; Goldstein JL; Schrott MG; Motulsky AG; Bierman EL
J Clin Invest; 1973 Jul; 52(7):1569-77. PubMed ID: 4352458
[TBL] [Abstract][Full Text] [Related]
13. [The relationship of cholesterol (CHO) and triglycerides (TG) in VLDL, LDL, and VLDL subfractions by agarose gel electrophoresis, using CHO and TG dual staining (AG-CHO, TG staining)].
Miyake N; Iizuka K
Rinsho Byori; 2002 Jun; 50(6):605-12. PubMed ID: 12166081
[TBL] [Abstract][Full Text] [Related]
14. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia.
Bruckert E; Dejager S; Chapman MJ
Atherosclerosis; 1993 Apr; 100(1):91-102. PubMed ID: 8318067
[TBL] [Abstract][Full Text] [Related]
15. Subclasses of low-density lipoprotein and very low-density lipoprotein in familial combined hyperlipidemia: relationship to multiple lipoprotein phenotype.
Georgieva AM; van Greevenbroek MM; Krauss RM; Brouwers MC; Vermeulen VM; Robertus-Teunissen MG; van der Kallen CJ; de Bruin TW
Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):744-9. PubMed ID: 14751815
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the sialic acid content of LDL as a marker of coronary calcification and extracoronary atherosclerosis in asymptomatic hypercholesterolemic subjects. PCVMETRA Group.
Chappey B; Myara I; Giral P; Kerharo G; Plainfosse MC; Levenson J; Simon A; Moatti N
Arterioscler Thromb Vasc Biol; 1995 Mar; 15(3):334-9. PubMed ID: 7749843
[TBL] [Abstract][Full Text] [Related]
17. Multiple-modified desialylated low density lipoproteins that cause intracellular lipid accumulation. Isolation, fractionation and characterization.
Tertov VV; Sobenin IA; Gabbasov ZA; Popov EG; Jaakkola O; Solakivi T; Nikkari T; Smirnov VN; Orekhov AN
Lab Invest; 1992 Nov; 67(5):665-75. PubMed ID: 1434544
[TBL] [Abstract][Full Text] [Related]
18. Serum and lipoprotein apolipoprotein B levels in normal subjects and patients with hyperlipoproteinaemia.
Durrington PN; Bolton CH; Hartog M
Clin Chim Acta; 1978 Jan; 82(1-2):151-60. PubMed ID: 201398
[TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity.
Kwiterovich PO
Am J Cardiol; 2002 Oct; 90(8A):30i-47i. PubMed ID: 12419479
[TBL] [Abstract][Full Text] [Related]
20. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability.
Bredie SJ; de Bruin TW; Demacker PN; Kastelein JJ; Stalenhoef AF
Am J Cardiol; 1995 Feb; 75(5):348-53. PubMed ID: 7856526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
